Foundation Medicine Inc (NASDAQ:FMI) CFO Jason Ryan sold 2,336 shares of the company’s stock in a transaction dated Tuesday, January 2nd. The shares were sold at an average price of $64.00, for a total transaction of $149,504.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.
Jason Ryan also recently made the following trade(s):
- On Tuesday, December 5th, Jason Ryan sold 21,726 shares of Foundation Medicine stock. The stock was sold at an average price of $61.26, for a total value of $1,330,934.76.
- On Thursday, November 2nd, Jason Ryan sold 9,731 shares of Foundation Medicine stock. The stock was sold at an average price of $50.00, for a total value of $486,550.00.
- On Thursday, October 12th, Jason Ryan sold 1,152 shares of Foundation Medicine stock. The stock was sold at an average price of $45.05, for a total value of $51,897.60.
Shares of Foundation Medicine Inc (NASDAQ FMI) opened at $64.95 on Friday. Foundation Medicine Inc has a 52-week low of $17.50 and a 52-week high of $70.75. The firm has a market capitalization of $2,285.73, a price-to-earnings ratio of -14.53 and a beta of -0.01. The company has a quick ratio of 2.03, a current ratio of 2.24 and a debt-to-equity ratio of 0.47.
Several large investors have recently added to or reduced their stakes in FMI. Lord Abbett & CO. LLC boosted its position in shares of Foundation Medicine by 146.0% in the 2nd quarter. Lord Abbett & CO. LLC now owns 579,225 shares of the company’s stock valued at $23,024,000 after purchasing an additional 343,770 shares during the period. Peregrine Capital Management LLC purchased a new stake in Foundation Medicine in the 3rd quarter worth about $13,299,000. State Street Corp lifted its stake in Foundation Medicine by 124.2% in the 2nd quarter. State Street Corp now owns 526,775 shares of the company’s stock worth $20,947,000 after acquiring an additional 291,815 shares in the last quarter. Baillie Gifford & Co. lifted its stake in Foundation Medicine by 42.0% in the 2nd quarter. Baillie Gifford & Co. now owns 248,300 shares of the company’s stock worth $9,870,000 after acquiring an additional 73,500 shares in the last quarter. Finally, Vanguard Group Inc. lifted its stake in Foundation Medicine by 8.2% in the 2nd quarter. Vanguard Group Inc. now owns 631,339 shares of the company’s stock worth $25,096,000 after acquiring an additional 47,843 shares in the last quarter. Institutional investors and hedge funds own 32.68% of the company’s stock.
A number of equities analysts have issued reports on FMI shares. BidaskClub raised Foundation Medicine from a “hold” rating to a “buy” rating in a research report on Wednesday, December 27th. Zacks Investment Research lowered Foundation Medicine from a “buy” rating to a “sell” rating in a research report on Wednesday. One analyst has rated the stock with a sell rating, two have assigned a hold rating and three have given a buy rating to the stock. Foundation Medicine presently has a consensus rating of “Hold” and a consensus target price of $45.33.
WARNING: “Jason Ryan Sells 2,336 Shares of Foundation Medicine Inc (FMI) Stock” was originally posted by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are viewing this news story on another site, it was illegally copied and republished in violation of U.S. and international copyright & trademark legislation. The original version of this news story can be accessed at https://www.chaffeybreeze.com/2018/01/05/jason-ryan-sells-2336-shares-of-foundation-medicine-inc-fmi-stock.html.
Foundation Medicine Company Profile
Foundation Medicine, Inc is a molecular information company. The Company sells products that are enabled by its molecular information platform to physicians and biopharmaceutical companies. It is engaged in the business of delivering molecular information about cancer to its customers. Its platform includes various methods and algorithms for analyzing specimens across various types of cancer.
Receive News & Ratings for Foundation Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Foundation Medicine and related companies with MarketBeat.com's FREE daily email newsletter.